Abstract
Background Total hip or knee replacement (arthroplasty) is common in ageing populations, as are prescribed opioids for osteoarthritis pain while awaiting such surgeries. Opioid-related harm can be minimised through pre-surgery tapering of opioids, yet the practice is uncommon.
Aim This research sought to understand GPs’ understandings, beliefs, and support needs around managing patients’ pain while awaiting surgery, use of opioids, and pre-surgery tapering.
Design & setting A qualitative study with GPs in Australia.
Method Semi-structured interviews were conducted. Data were transcribed, deidentified, and reflexively analysed inductively and thematically.
Results Analysis of transcript data from GP interviews (n =17) revealed little knowledge of, yet positive support for, pre-arthroplasty opioid tapering as a further way to minimise opioid harm. Three themes described were: 1) feeling challenged by pre-surgery pain management and opioid prescribing; 2) optimal pain management and tapering prevented by patient-related and system-level barriers; and 3) sharing workload and perceived risk — pharmacists could provide opioid management support.
Conclusion Realisation of potential opioid tapering benefits will require addressing some personal-, patient-, and system-level barriers revealed by this study. GPs view support from pharmacists as valuable and welcomed yet the required collaborative models appear, currently, underdeveloped between these primary care professions. Implementation research is a crucial next area of inquiry.
How this fits in
Opioids are prescribed, despite guideline concerns, to manage pain for people waiting for arthroplasty. Despite being unaware of pre-surgery deprescribing, GP participants were supportive, yet perceived patient- and system-level barriers. Pharmacist-partnered tapering was viewed as a pragmatic way to share workload and risk, aligning with emerging evidence. The findings from this research inform shared-care models in primary care that are feasible.
Introduction
Opioids are commonly prescribed as part of pre-surgery management of osteoarthritis-related pain in a significant proportion of patients awaiting hip or knee replacement surgeries (arthroplasty),1 despite limited evidence for efficacy in this population, increased risk of harm, and clinical guidance advising against their use.2–4 Evidence associates use of opioids before arthroplasty with worse postoperative outcomes, including pain intensity and physical function,5 and an increased risk of postoperative complications such as prosthesis revision.6,7 Additionally, opioid use before surgery is linked to a greater incidence of opioid use 3 months after surgery and beyond.8 Total hip or knee arthroplasties are among the most frequently performed procedures globally, projected to rise by 174% and 673% respectively by 2030 in developed countries.9–13
The views of GPs on the management of people’s osteoarthritis-related pain pre-arthroplasty are little understood, yet primary care is mostly where this management occurs.14 Some evidence suggests GPs are challenged by providing pre-surgery patient support articulated in guidelines, including weight loss and physical conditioning, as these interventions are time-intensive and poorly funded.15 In some settings, such as outside metropolitan areas, reduced access to specialised healthcare resources such as pain or obesity clinics increases the pressures on primary care.16
Harm minimisation from opioids and opioid stewardship are shared responsibilities of healthcare practitioners and, additionally, the theoretical assumptions underpinning this research. Interventions in primary care to taper opioids pre-arthroplasty have limited but emerging evidence that they reduce opioid use.17,18 Pain management and support for patients waiting for total hip or knee arthroplasty occurs in general practice. It is thus timely to explore the views of GPs about this area of practice. This study, therefore, aimed to qualitatively explore GPs’ understandings and beliefs on pre-arthroplasty opioid management and tapering. As the emerging evidence in primary care includes a pharmacist-partnered model of pre-arthroplasty opioid tapering (proportion tapered 90% versus 17%; P<0.01),17 this study also included GPs’ views of partnering with pharmacists.
Method
A qualitative approach was taken to allow an in-depth exploration of the understandings and beliefs of Australian GPs. We agreed on a constructionist epistemological approach, where researcher reflexivity and subjectivity is acknowledged, and knowledge is actively constructed with the research participants in the context of the research question and the interview interactions.19,20 Ethics approval was obtained from the South-Western Local Health District Human Research Ethics Committee (2021/ETH00343). OpioidHALT trial (ACTRN12621000919819). The COnsolidated criteria for REporting Qualitative research (COREQ) checklist guided the research and reporting.
We contacted, via email and/or telephone, all participant GPs (n =60) from the OpioidHALT pilot study,17 invited participation and provided study information. Recruiting GPs is a recognised challenge in qualitative research. Only two study GPs consented to interview, and recruitment strategies were expanded to sample all Australian GPs through snowballing (beginning with the broader research team’s networks and pain conference attendees). We considered all GPs as having experience with managing patients pre-arthroplasty due to the high prevalence of this surgery.21 Study participants were informed the research was collecting interview data on opioid management and tapering pre-arthroplasty, and on potential pharmacist support. The interviewer (SH) was not involved in the pilot study and had no prior relationship to any participants. Participants received a voucher for their time and inconvenience at a reasonable and proportional rate in accordance with the Australian National Health and Medical Research Council 2019 guidance (AUD $200).22
A single in-depth, semi-structured individual interview was conducted with each participant by the first author (March–June 2023) by telephone or video call, and was audio-recorded. An interview guide was developed to answer the research question and included how GPs manage osteoarthritis pain in their patients waiting for hip or knee arthroplasty; approaches to opioid use; their understanding and experience with opioid tapering; and views on pharmacist support (Table 1). Following each interview, field notes were taken to initiate reflection and understanding.
Microsoft Word and Excel were used to manage and organise the data. Data were transcribed verbatim and reflexive thematic analysis was conducted inductively.23 First, all interview transcripts were read by the first author. Initial themes and concepts and their meanings were noted and described, and a coding framework was developed where text was organised into categories and subcategories. Analysis to develop final themes and meanings followed an iterative process, including comparison across and within categories, review and refinement of categories against primary data, and defining and naming of themes for further review and refinement leading to the final written findings. The first author discussed findings with the broader research team and qualitative research experts during the analysis, in line with a reflexive approach, to challenge individual interpretations and develop themes.
The research team included multiple professional and research disciplines, with many years’ experience in practice and/or research of orthopaedic patients or patients with osteoarthritis. We reflexively considered our impact on the research and were guided by an overall goal to provide a fair and robust representation of the participants’ views, experience, and context. The interviewer (SH) presented to interview participants as a qualitative researcher seeking to understand the views of GPs, who were free to speak candidly as their responses would be deidentified prior to analysis and dissemination. His professional identity as a registered pharmacist was not hidden from participants.
Results
Seventeen interviews (25–35 minutes each) were conducted with GPs, of whom 12 were female, 11 were city-based (metropolitan), and 2 had participated in the OpioidHALT study (Table 2). The interview data revealed a consensus among the GP participants about the need to further minimise opioid harm through implementation of pre-arthroplasty opioid tapering. In the following sections, three main themes that resulted from the analysis of GPs’ interviews are described: 1) feeling challenged by pre-surgery pain management and opioid prescribing; 2) optimal pain management and tapering prevented by patient-related and system-level barriers; and 3) sharing workload and risk – pharmacists could provide opioid management support.
Theme 1: Feeling challenged by pre-surgery pain management and opioid prescribing
GPs initially expressed confidence in how they managed and safeguarded opioids and the way they prescribed opioids for their patients. They emphasised how little they initiated prescribed opioids in their patients and referenced changes to contemporary opioid use and management that now guide their practice. They provided specific details about how they personally managed risk when they did prescribe opioids that included use of low doses, small quantities, short-acting formulations, ‘when necessary’ directives, and much patient education. The downplaying of their own opioid prescribing contrasted with their descriptions of opioid prescribing that they noticed in some other practitioners and peers. An example of this is GPs referring to ‘challenging’ patients they were currently treating with higher doses of opioids as being ‘inherited’ from other GPs who were responsible for initiating the higher doses of opioids:
‘… we've actually evolved in the way we look at pain management in patients with chronic pain. … there would be a small group of patients … we'll find ourselves reluctantly, prescribing opioids…’ (GP 1)
‘I try not to go too high, obviously. But obviously that fear factor of, sort of dependence and sort of side effects. … Yeah, so I think that’s sort of the challenge we face.’ (GP16)
‘I do a lot of education for patients needing hip replacement as to … why they're in pain … I think that can be really useful … of course the surgeons are doing [education] as well. But it does help to hear [it] multiple times...’ (GP10)
‘Occasionally, I inherit a patient who has, who’s already on opioids, prior to joint replacement surgery. And I find them really difficult because once started, they're very reluctant to come off.’ (GP10)
When asked, GPs were generally unaware of notions of pre-arthroplasty opioid tapering to improve post-surgery outcomes, stating this was probably because it was not part of the medical training they had received, or of their practice experience. While interested in the potential benefits, they expressed hesitancy about trying tapering with their patients. Their reluctance centred on beliefs that tapering meant providing inadequate patient care during a period of high need for care:
‘… if I had a patient that was coming up to their date of surgery, I wouldn't have thought to wean it down … obviously, I wouldn't want the pain to flare significantly right before the operation.’ (GP 7)
‘… I've heard about like, tapering, obviously post-surgical … but not really pre surgery.’ (GP 4)
GPs expressed uncertainty about how they would approach the task of tapering. They questioned how they would ‘convince’ patients to taper, and how they would find the expected time and effort it would require. They expanded by stating that time would be needed to give additional patient education and counselling to ensure better understanding of opioids and their benefits and risks. GP 3 was an outlier, having gained confidence through experience in pain clinics:
‘It takes sometimes weeks to wean someone off … And the patient usually has to be in the right mindset to go through it as well. … how do you convince someone to deal with pain?’ (GP 13)
‘… saying “I'm going to take you off this” before they have the operation would take a lot of counseling.’ (GP 15)
‘… I usually try halve their sustained release and see how they go after a week. And then if they can tolerate that I halve it again just depending on what sort of levels they're on. ... I do it pretty quickly over a couple of weeks.’ (GP3)
Theme 2: Optimal pain management and tapering prevented by patient-related and system-level barriers
GP participants discussed many factors they believe negatively impact their ability to deliver what they considered optimal pain management practice for their patients with osteoarthritis waiting for surgery. They spoke of patients’ flawed expectations, goals, and beliefs around pain and opioids, and of their resistance to minimising opioids. Additionally, and particularly for publicly-funded patients, GPs reported feelings of powerlessness against system-level barriers reducing access to care. GP 12 suggested inequity in chronic pain care was an exemplar of broader underresourcing of primary care:
‘… if patients have the expectation that they're going to be pain free … then there’s often a mismatch between our respective goals...’ (GP8)
‘…psychologically, they're so intent upon keeping on this medication ‘cause they do really believe that they need it. That’s probably the biggest issue.’ (GP 2)
‘… there’s not a lot of support out there for GPs in the area of chronic care. We can't offer … the gold standard treatment … because the resources aren't there.’ (GP 12)
GPs’ descriptions of the patient-related factors that influence pre-surgery management included patients’ social contexts and emotional traits. They suggested a perceived increased ‘need’ for opioids was linked to low socioeconomic status, low health literacy, and manual jobs. GPs further linked patient desire to alleviate pain with traits such as low pain tolerance, low resilience, and wilful ignorance of risk:
‘… often patients that don't have private health insurance tend to have lower levels of health literacy, and therefore I tend to find … less open to explanations … they are harder to convince, as to the benefits of weight loss and allied health as a mechanism of managing pain and function prior to surgery.’ (GP 10)
‘… half of the people are pretty aware [of risks] … the other 50% are people that are also smoking and drinking or might be using drugs or already on a lot of medications. And they … don't mind or they don't think about side effects. They just think about the short-term effects.’ (GP6)
‘… I've got a chef who weighs 200 kg, waiting for bariatric surgery and his knees are giving out on him because he’s working, you know, seven days a week. He does need the PRN [as needed] Endone from time to time just to help him, you know, get by with work.’ (GP 9)
GPs’ discussions of system-level factors affecting pre-surgery pain management were primarily around funding, particularly whether patients were ‘public’ (publicly-funded) or private-paying. GPs revealed that ‘private’ patients were afforded more consultation time and this could be used for ‘non-drug‘ care, such as education and referrals for exercise and diet support. As such, this support was likely to result in less prescribing of pain medicine. Additionally, private patients had shorter wait times for surgery and thus shorter times requiring pain management:
‘… the fact that we have gone private billing means that we have more time to spend on patients to educate them … it’s [public health] not remunerated well to talk. …unfortunately, the easiest way is to give a drug sometimes to kind of get them [public health patients] out the door.’ (GP 9)
‘… it’s most people [who are prescribed opioids] that don't have private health funds, because they've had to wait longer [for surgery]. So, then they get to the point where simple analgesia isn't enough, and they're in a lot of pain.’ (GP 15)
Wait times were also a factor to consider with tapering. GPs noted that trying to plan and enact tapering with little knowledge of surgery dates, such as for public patients, would be challenging. They empathised with long waits for GP appointments in some rural areas that may not align with short surgery notifications and tapering regimens.
‘One of the difficulties [to tapering] that I would have, in a public hospital waiting list, is not knowing the date of surgery at all, and so helping patients who are quite fearful of withdrawing from opioids without having a length to be able to talk them through, I think would be a major barrier.’ (GP17)
‘… often patients will get maybe two weeks’ notice for the joint replacement, and … it takes two months to get an appointment with me.’ (GP8)
Theme 3: Sharing workload and risk – pharmacists could provide opioid management support
When asked, GPs expressed enthusiasm for gaining support with patient opioid management and with tapering. They envisaged the most useful benefits would be to overall workload reduction and the sharing of responsibility and risk for opioid management. They believed pharmacists’ support would make a significant difference to the time they spent providing patient education while also improving care through reinforcing messages and patient motivation:
‘I think that would be a huge advance, because then you wouldn't have to take that ownership and that burden of trying to, like, fight it on your own … not only do you have more support, but the patient also has more faith. … I think a team approach is always better.’ (GP 4)
‘… it’s certainly such a drain on my time having to speak to people for long periods of time, over and over again.’ (GP 2)
‘… if pharmacists can provide patient education, about tapering the opioid analgesia … then when patients come to see us for scripts, then the patient’s already well educated, and is more willing to tapering off a medicine … I think that’s a great idea.’ (GP 5)
GPs described general practice as isolating and often lacking in team care. They saw pharmacists as supportive colleagues who share their knowledge and help build GPs’ confidence in challenging areas of practice such as opioid management. When asked how collaboration could be facilitated, GPs believed effective and regular communication was most important, yet also noted technology and timing as being barriers to its achievement.
‘… I also think they're [pharmacists] probably good at setting some parameters for the doctor who might be a little bit unsure, you know, about how fast or slow to go, and that sort of thing.’ (GP 12)
‘… overall, more pharmacy inputs in how doctors prescribe medications that have like a lot of side effects and that are addictive, I think it’s, it’s good. That collaboration is good.’ (GP6)
‘Phone calls are always very difficult because GPs have back-to-back appointments and it’s like, how are you getting that timing right between the pharmacist and the GP … we do have a pharmacist in house, but they're not on that [in-house] messaging system.’ (GP 7)
GPs expressed concerns about sharing responsibility and how this would occur in practice. For example, some GPs wanted assurance pharmacists’ decisions would not be autonomous while others suggested pharmacists and patients could and should manage tapering, noting that tapering requires flexibility and an ongoing time commitment that GPs are less able to provide:
‘I think there has to be good communication between the two [GP and pharmacist], and I think that that responsibility … There needs to be a true collaborative approach to it, otherwise you'll get one deferring the responsibility to the other … I think ultimately the prescriber should have the responsibility but utilise the pharmacists as education ...’ (GP 3)
‘… it’s really up to the general practice to decide on how they wish to wean the patient or manage the patient.’ (GP13)
GPs noted that some of their colleagues held negative opinions of pharmacists around conflict of interest and duty of care, and around pharmacists’ practice scope, that would prevent some GPs from collaborating. They believed, however, that these issues could be overcome where effective relationships exist or are developed:
‘I suppose some doctors would say, oh, it’s the thin edge of the wedge, and they're [pharmacists] taking work away from us, like immunising people and so on. … but since no one wants to be a GP anymore, we can't possibly cope with this workload...’ (GP 2)
Discussion
Summary
This study exploring GPs’ understandings and beliefs around management of osteoarthritis pain while waiting for hip and knee arthroplasty exposed some of the personal and contextual challenges experienced by GPs supporting this patient cohort. Despite the GP participants regularly seeing patients taking opioids for pre-arthroplasty pain, we found little awareness of opioid tapering as a pre-arthroplasty clinical activity and of the clinical justification for doing so and, as such, little direct experience in this practice. Throughout the interviews, however, GPs positively assessed pre-arthroplasty opioid tapering and the benefits around post-surgery pain management and risk reductions that may result from lower opioid exposure at the time of surgery. Their assessment of tapering benefits aligned with their acknowledgement of the need for opioid harm minimisation and reticence to prescribe opioids, in line with guidance in Australia and globally.4,24 The GPs revealed numerous challenges to tapering that may require addressing to achieve its integration into routine primary care. These included GPs’ beliefs that personal-, patient-, and system-wide barriers would prevent its success in many patients. A potential pharmacist’s supporting role was seen positively by the GPs interviewed. Formal implementation, however, was perceived by the participants as requiring collaborative care models between GPs and pharmacists that are not routinely utilised in current Australian primary care.
Strengths and limitations
A strength of this research is that it captured in-depth explorative interviews with seventeen GPs working across diverse geographic areas in Australia. This study provides new knowledge on this previously underresearched area of practice. It does not seek to be generalisable, yet the challenges faced by the participant GPs may resonate in other health jurisdictions. A limitation of this research, while not measured, is that many GPs were recruited by snowballing and this may have limited the sample diversity, which slightly overrepresented female GPs versus the general GP population. Given the well-reported challenges of recruiting GPs into studies, an informed and pragmatic view was formed by the researchers that adequate sampling was achieved to answer the research question. The authors acknowledge that the lead author’s (SH) previous research into practitioner-led chronic condition self-management care, and his practice as a pharmacist, will have shaped the interviews, analysis, and manuscript writing. The lead author and interviewer’s pharmacist identity may have had a confounding effect by tempering participant responses; this was not apparent, however, despite some participants acknowledging it in some responses. Deliberate and regular discussion with the multidisciplinary research team and network of peers promoted the challenging of underlying assumptions during each stage of the research.
Comparison with existing literature
The GPs interviewed viewed their patients seeking relief from hip and knee pain as challenging, and felt that an extension of that challenge was the management of those patients that had been initiated on opioids. Tapering opioids, while considered theoretically good for patient outcomes, was viewed as an even further challenge. GPs’ concerns around tapering opioids were frequently reduced to the time and effort for education and the ‘convincing’ of patients they believed would be required, on top of the time and effort they already spend with these patients. These concerns were shaped by the contemporary primary care context of diminishing resources and high workloads, a context shared across similar publicly funded healthcare systems globally. These findings further those of a qualitative study exploring the challenges clinicians perceive to reducing opioids more broadly in primary care.25 Similar barriers were identified concerning the patient, prescriber, and health system.25 As a result of these challenges, participants of both studies perceived opioid tapering in primary care as a complex problem as yet unsolved. The present study adds to the existing literature by revealing GPs’ willingness to reduce their current responsibility and the risk they associate with being solely responsible for their patients’ opioid management.
The clear organic causal pathology of pain associated with hip and knee conditions requiring arthroplasty, however, differentiates it from pain where its existence is contested between patient and practitioner such as chronic lower back pain.26 Indeed, the participant GPs spoke of the pain diagnosis in this cohort within an objective biomedical and/or biomechanical lens. Where GPs displayed a subjective psychosocial approach was in their conceptualisation of patients’ varying abilities to tolerate pain, willingness to try non-pharmacological pre-surgery activities such as exercise and weight loss, and need for opioid pain relief. Their focus on these psychosocial aspects of pain self-management was seen to be shaped by objective inequalities between their privately-insured patients and those only accessing public healthcare. GPs in this study revealed that private health insurance affords shorter waits for surgery and greater opportunity for non-pharmacological pre-surgery care and, thus, less need for opioids. GPs’ exemplars of publicly-funded patients — whom they described as ‘needing’ opioids for various social and emotional reasons — and their fears of ‘undertreatment’ of their pain if opioids were tapered fit within a subjective psychosocial model of assessment of potential candidates for tapering that might achieve success. In contrast to the participant GPs’ views of patient resistance to addressing opioid use, recently published views of the patient participants of the OpioidHALT study reveal a different relationship to their opioid use.27 These patients spoke of being challenged by needing to take opioids, the inadequate response to their pain that opioids provide, the side effects they have experienced, and their ongoing fear of becoming addicted. This appears to show areas of disconnect with the views of GP participants in this study, who perceived patient resistance to tapering opioids and harm minimisation. Only half the patient study participants volunteered to be interviewed, however, potentially misrepresenting the importance of this finding.
Implications for research and practice
GPs in this study, acknowledging a challenging area of practice in a challenging health system context, expressed their willingness to try novel collaborative methods to achieve both GP and patient benefits. When asked, they were positive about gaining the support of pharmacists for opioid tapering, identifying practical and workload reasons.2 They noted, however, that pharmacist-partnered opioid tapering implementation would need to overcome several challenges, particularly around methods of communication and interprofessional tensions. Australian primary care has evolved, as in other health jurisdictions, to include pharmacist roles in general practice and has expanded scope of practice for pharmacists in areas such as vaccination and prescribing. Public commentary between the professional bodies and key opinion leaders in Australia demonstrates that acceptance is not universal, a point referred to by some participants. The participants experienced, however, effective GP–pharmacist work practices, and these tended to rely on existing and individual trusting relationships, mainly those in close geographical proximity to their practices. This suggests tensions at a professional level are not always felt within communities. In contrast, there was little discussion around there being effective structures for, or cultures of, collaboration at a professional governance level between primary care pharmacists and GPs.
This research provides guidance for GPs and primary care. Identification of patients who are regularly taking opioids before hip and knee replacement surgery could lead to open discussions of the benefits and harms of continued opioid use, and of tapering where desirable. Patients have expressed that they receive little benefit from regular opioid use and, in the absence of support to taper, continue taking them.27,28 GPs may additionally consider a range of supports such as perioperative clinics, pain teams, and digital tapering supports depending on availabilities and local contexts. A pharmacist-partnered service to taper opioids before surgery, as we proposed to the GP participants, may be a viable strategy to address existing unmet support needs of general practice. In deprescribing more broadly, pharmacist-partnered services have been shown to reduce the use of one additional medication per patient when compared to GP-only clinical audits.2 Additionally, two randomised trials in the primary care setting demonstrated that pharmacist-partnered opioid tapering resulted in safe opioid dose reductions of at least 50% of the baseline opioid dose: the number of patients who successfully decreased their baseline daily opioid dose by ≥ 50% before surgery was n = 27/30 in the intervention group compared with n = 5/30 in the usual care group (P<0.001).2,17
This research reveals its GP participants’ management of pain and opioids prior to hip or knee arthroplasty as a challenging and time-consuming area of practice. Pre-surgery opioid tapering is mostly absent and, while accepting benefits, GPs expressed doubts around achieving success for reasons of the perceived time required to support tapering, health system factors, and perceived clinical and psychosocial needs of the patients they assessed as needing opioids. GPs welcomed external support from pharmacists to taper opioids around education and the sharing of what they perceived as the risk of opioid prescribing, yet noted that appropriate models for collaboration with pharmacists are not currently conceived. Further research to identify an effective model may facilitate broader implementation and result in improved surgical patient outcomes.
Notes
Funding
The study was funded by an AVANT Foundation Research Grant (2021/000135). The organisation had no influence on the study design, analysis, or publication.
Ethical approval
Ethics approval was obtained from the South-Western Local Health District Human Research Ethics Committee (2021/ETH00343). OpioidHALT trial (ACTRN12621000919819).
Author Contributions
All authors have approved the submitted version and have agreed both to be personally accountable for the author's own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature.
Provenance
Freely submitted; externally peer reviewed.
Data
The datasets generated during and/or analysed during the current study are not publicly available due to privacy and lack of consent from participants for this purpose.
Consent for publication
Participants provided written consent to be audiorecorded, for recordings to be transcribed and deidentified, and for data to be analysed and disseminated in academic journals and conference presentations.
Acknowledgements
The authors acknowledge the GP participants who gave of their time for this research.
Competing interests
The authors declare that no competing interests exist.
- Received August 8, 2025.
- Revision received September 22, 2025.
- Accepted November 12, 2025.
- Copyright © 2026, The Authors
This article is Open Access: CC BY license (https://creativecommons.org/licenses/by/4.0/)






LinkedIn